These studies show that a physiologically relevant dose of
dietary EGCG reduces the development of obesity, hyperglycemia,
insulin resistance, hypercholesterolemia, and hepatic steatosis
in high-fat–fed mice. They also suggest that EGCG treatment
may reverse the effects of a high-fat diet on BW and blood
glucose. These effects may be related to decreased fat absorption
and antiinflammatory effects mediated by EGCG. Other possible
mechanisms such as decreased fatty acid synthesis and
increased fatty acid oxidation need further investigation. It will
also be interesting to determine how EGCG restores glucose
homeostasis and attenuates fatty liver disease. Finally, it will be
important to clearly determine whether our presently observed
effects occur in humans and whether EGCG or green tea
consumption can be used as a tool to prevent the development of
obesity and its comorbidities.